MA40761B1 - Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr - Google Patents
Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfrInfo
- Publication number
- MA40761B1 MA40761B1 MA40761A MA40761A MA40761B1 MA 40761 B1 MA40761 B1 MA 40761B1 MA 40761 A MA40761 A MA 40761A MA 40761 A MA40761 A MA 40761A MA 40761 B1 MA40761 B1 MA 40761B1
- Authority
- MA
- Morocco
- Prior art keywords
- fgfr
- responsive
- treatment
- cancer patients
- mutant gene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Cette invention concerne des méthodes d'identification d'un patient atteint de cancer qui sera sensible au traitement avec un inhibiteur du récepteur du facteur de croissance des fibroblastes (fgfr) et des méthodes destinées à traiter des patients atteints de cancer. Les méthodes impliquent l'évaluation d'un échantillon biologique provenant du patient pour identifier la présence d'un ou de plusieurs mutants du fgfr à partir d'un panel de gènes mutants du fgfr. Des kits et des amorces pour identifier la présence d'un ou de plusieurs gènes mutants du fgfr dans un échantillon biologique sont également décrits.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056159P | 2014-09-26 | 2014-09-26 | |
| PCT/US2015/050996 WO2016048833A2 (fr) | 2014-09-26 | 2015-09-18 | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40761A MA40761A (fr) | 2017-08-01 |
| MA40761B1 true MA40761B1 (fr) | 2022-04-29 |
Family
ID=54337343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40761A MA40761B1 (fr) | 2014-09-26 | 2015-09-18 | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US20160090633A1 (fr) |
| EP (2) | EP3198033B1 (fr) |
| JP (4) | JP6766037B2 (fr) |
| KR (3) | KR102470456B1 (fr) |
| CN (2) | CN107002141B (fr) |
| AR (1) | AR102345A1 (fr) |
| AU (3) | AU2015321626B2 (fr) |
| CA (2) | CA2962075C (fr) |
| CO (1) | CO2017003528A2 (fr) |
| CR (1) | CR20170104A (fr) |
| CY (1) | CY1125190T1 (fr) |
| DK (1) | DK3198033T3 (fr) |
| EA (1) | EA037920B1 (fr) |
| EC (1) | ECSP17025787A (fr) |
| ES (1) | ES2912567T3 (fr) |
| GT (1) | GT201700059A (fr) |
| HR (1) | HRP20220496T1 (fr) |
| HU (1) | HUE058219T2 (fr) |
| IL (3) | IL291633B2 (fr) |
| JO (1) | JO3681B1 (fr) |
| LT (1) | LT3198033T (fr) |
| MA (1) | MA40761B1 (fr) |
| MX (2) | MX392774B (fr) |
| MY (1) | MY194567A (fr) |
| NI (1) | NI201700035A (fr) |
| PH (1) | PH12017500556A1 (fr) |
| PL (1) | PL3198033T3 (fr) |
| PT (1) | PT3198033T (fr) |
| RS (1) | RS63178B1 (fr) |
| SG (1) | SG11201702381QA (fr) |
| SI (1) | SI3198033T1 (fr) |
| SM (1) | SMT202200177T1 (fr) |
| SV (1) | SV2017005415A (fr) |
| TW (1) | TWI706136B (fr) |
| UA (1) | UA122564C2 (fr) |
| UY (1) | UY36325A (fr) |
| WO (1) | WO2016048833A2 (fr) |
| ZA (1) | ZA201702899B (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2886002C (fr) | 2012-09-27 | 2020-06-09 | Chugai Seiyaku Kabushiki Kaisha | Gene de fusion fgfr3 et medicament pharmaceutique ciblant celui-ci |
| EP3098312B1 (fr) * | 2014-01-24 | 2023-07-19 | Japanese Foundation For Cancer Research | Nouvelle élément de fusion et son procédé de détection |
| MA39784B1 (fr) | 2014-03-26 | 2021-03-31 | Astex Therapeutics Ltd | Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer |
| CR20170104A (es) | 2014-09-26 | 2017-05-31 | Janssen Pharmaceutica Nv | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr |
| JO3695B1 (ar) | 2015-02-10 | 2020-08-27 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين) |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3424505A4 (fr) * | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | Préparation et composition de traitement de tumeurs malignes |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| EP3639039A4 (fr) | 2018-07-27 | 2021-05-19 | Zepto Life Technology, LLC | Système et procédé de détection basée sur gmr de biomarqueurs |
| EA202190826A1 (ru) * | 2018-09-21 | 2021-06-16 | Янссен Фармацевтика Нв | Лечение холангиокарциномы |
| CN113423402A (zh) * | 2019-02-12 | 2021-09-21 | 詹森药业有限公司 | 癌症治疗 |
| EP3946340A1 (fr) | 2019-03-29 | 2022-02-09 | Janssen Pharmaceutica NV | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial |
| CN113645974A (zh) * | 2019-03-29 | 2021-11-12 | 詹森药业有限公司 | 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂 |
| US20220233537A1 (en) * | 2019-05-31 | 2022-07-28 | Qed Therapeutics, Inc. | Methods of treating urinary system cancers |
| CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
| US20220267452A1 (en) * | 2019-07-12 | 2022-08-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-mutation type fgfr3 antibody and use therefor |
| CN115335701A (zh) * | 2019-09-09 | 2022-11-11 | 泽普托生命技术有限责任公司 | 用于检测核酸中基因变异的系统和方法 |
| US20220348662A1 (en) | 2019-09-26 | 2022-11-03 | Janssen Pharmaceutica Nv | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
| US12600825B2 (en) | 2020-01-08 | 2026-04-14 | Zepto Life Technology, Inc. | Polymer compositions and biosurfaces comprising them on sensors |
| TWI900527B (zh) | 2020-02-12 | 2025-10-11 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| PH12022552093A1 (en) * | 2020-02-12 | 2023-11-29 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| AU2021254793A1 (en) * | 2020-04-15 | 2022-11-17 | Clovis Oncology, Inc. | Immunostimulatory agents in combination with angiogenesis inhibitors |
| CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
| US20230321087A1 (en) | 2020-09-14 | 2023-10-12 | Janssen Pharmaceutica Nv | Fgfr inhibitor combination therapies |
| CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
| US20250000858A1 (en) | 2021-05-19 | 2025-01-02 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
| EP4415692A1 (fr) | 2021-10-12 | 2024-08-21 | TARIS Biomedical LLC | Formulations d'erdafitinib et systèmes d'administration intravésicale |
| KR20240145513A (ko) | 2022-02-18 | 2024-10-07 | 타리스 바이오메디컬 엘엘씨 | 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템 |
| EP4665342A1 (fr) | 2023-02-13 | 2025-12-24 | TARIS Biomedical LLC | Erdafitinib pour administration intravésicale destiné à être utilisé dans le traitement du cancer de la vessie |
| CN120813357A (zh) | 2023-02-13 | 2025-10-17 | 詹森药业有限公司 | 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂 |
| JP2026506041A (ja) | 2023-02-17 | 2026-02-20 | タリス バイオメディカル エルエルシー | 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ |
| WO2025059602A1 (fr) | 2023-09-14 | 2025-03-20 | Taris Biomedical Llc | Méthodes de traitement du cancer de la vessie à l'aide d'une administration intravésicale d'erdafitinib |
| CN119219611B (zh) * | 2024-12-03 | 2025-04-18 | 南京诺源医疗器械有限公司 | 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| AU5214500A (en) | 1999-05-05 | 2000-11-21 | Centre National De La Recherche Scientifique (C.N.R.S.) | Means for detecting and treating pathologies linked to fgfr3 |
| CA2500255A1 (fr) | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Procede et acides nucleiques permettant d'ameliorer le traitement de troubles de la proliferation de celllules mammaires |
| EP1611252B1 (fr) * | 2003-03-26 | 2009-07-29 | Progenika Biopharma, S.A. | Methode de detection in vitro du carcinome a cellules transitionnelles de la vessie |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1659175A1 (fr) * | 2004-11-18 | 2006-05-24 | Institut Curie | Altérations des kératoses séborrhéiques et applications dérivées |
| EP2270000B1 (fr) | 2005-05-23 | 2015-07-29 | Novartis AG | Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one |
| WO2007061127A1 (fr) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | Agent antitumeur pour myelomes multiples |
| EP2546359A1 (fr) * | 2005-12-08 | 2013-01-16 | Novartis AG | Effets d'inhibiteurs de FGFR3 sur la transcription génétique |
| EP1918376A1 (fr) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques |
| US20100075337A1 (en) | 2007-02-27 | 2010-03-25 | Diana Graus Porta | Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereof |
| WO2008109369A2 (fr) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| JP5282088B2 (ja) | 2007-06-21 | 2013-09-04 | ジェン−プロウブ インコーポレイテッド | 処理実行に使用する機器および容器 |
| US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| WO2013173480A1 (fr) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Détection de récurrence de cancer de la vessie |
| WO2013173485A1 (fr) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Détection de cancers de la vessie |
| GB0718542D0 (en) | 2007-09-22 | 2007-10-31 | Univ Dundee | Targeted modulation of gene expression |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| WO2010111625A1 (fr) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions et procédés permettant d'utiliser des protéines de liaison multispécifiques comprenant une combinaison anticorps-récepteur |
| WO2011027219A1 (fr) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | Détection à rendement élevé de petites délétions et insertions génomiques |
| EP2547698B1 (fr) * | 2010-03-14 | 2015-07-29 | The Translational Genomics Research Institute | Procédés de détermination de la sensibilité de tumeurs à des inhibiteurs de la tyrosine kinase |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
| CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释－缓释渗透泵制剂 |
| KR20140057343A (ko) | 2011-08-18 | 2014-05-12 | 네스텍 소시에테아노님 | 대립형질 변이 검출을 위한 조성물 및 방법 |
| EP2761300A4 (fr) * | 2011-09-27 | 2015-12-02 | Univ Michigan | Fusions de gènes récurrentes dans le cancer du sein |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013088191A1 (fr) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3 |
| UA114501C2 (uk) * | 2012-02-28 | 2017-06-26 | Астеллас Фарма Інк. | Азотовмісна ароматична гетероциклічна сполука |
| BR112014021897B1 (pt) | 2012-03-08 | 2022-06-14 | Astellas Pharma Inc | Método, kit, conjunto de iniciadores e conjuntos de sondas para detectar um gene de fusão composto por um gene fgfr3 e um gene tacc3 |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2871236A4 (fr) * | 2012-07-05 | 2016-03-09 | Nat Cancer Ct | Gène fgfr2 hybride |
| ES2932954T5 (en) * | 2012-07-24 | 2025-10-28 | Univ Columbia | Fgfr-tacc fusion proteins and methods thereof |
| US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| CA2886002C (fr) * | 2012-09-27 | 2020-06-09 | Chugai Seiyaku Kabushiki Kaisha | Gene de fusion fgfr3 et medicament pharmaceutique ciblant celui-ci |
| WO2014071419A2 (fr) * | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Nouvelles molécules de fusion et leurs utilisations |
| WO2014113729A2 (fr) * | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Méthodes de traitement du cholangiocarcinome |
| EP2981621B1 (fr) | 2013-04-05 | 2019-05-22 | Life Technologies Corporation | Fusions géniques |
| WO2014193229A2 (fr) | 2013-05-27 | 2014-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Nouvelles translocations dans le cancer du poumon |
| EP3019628A4 (fr) | 2013-07-12 | 2017-05-10 | The Regents Of The University Of Michigan | Fusions de gènes récurrentes dans le cancer |
| US20200208224A1 (en) | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| CR20170104A (es) | 2014-09-26 | 2017-05-31 | Janssen Pharmaceutica Nv | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr |
| HRP20230697T1 (hr) | 2017-02-06 | 2023-10-13 | Janssen Pharmaceutica Nv | Liječenje karcinoma |
-
2015
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 SM SM20220177T patent/SMT202200177T1/it unknown
- 2015-09-18 CA CA2962075A patent/CA2962075C/fr active Active
- 2015-09-18 IL IL291633A patent/IL291633B2/en unknown
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active Active
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 KR KR1020227040649A patent/KR102839867B1/ko active Active
- 2015-09-18 IL IL324511A patent/IL324511A/en unknown
- 2015-09-18 KR KR1020257024958A patent/KR20250119657A/ko active Pending
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 CA CA3275619A patent/CA3275619A1/en active Pending
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/fr not_active Ceased
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/fr active Active
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/fr active Pending
- 2015-09-18 CN CN202111247854.6A patent/CN113957146B/zh active Active
- 2015-09-18 MX MX2017003954A patent/MX392774B/es unknown
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US12037644B2/en active Active
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633B2/en active Active
-
2022
- 2022-03-30 JP JP2022056709A patent/JP7558216B2/ja active Active
- 2022-04-29 CY CY20221100314T patent/CY1125190T1/el unknown
-
2024
- 2024-05-28 US US18/675,538 patent/US20240309463A1/en active Pending
- 2024-05-30 JP JP2024087917A patent/JP2024112991A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201448A patent/AU2025201448A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3681B1 (ar) | استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr | |
| Chouraki et al. | Genetics of Alzheimer’s disease | |
| WO2008088854A3 (fr) | Marqueurs génétiques pour la prédiction de sensibilité à une polythérapie | |
| MX2022014633A (es) | Metodos para detectar norovirus. | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| AR099856A1 (es) | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado | |
| PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| DK2413142T3 (da) | Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor | |
| WO2008073177A3 (fr) | Profils d'expression génique et protéique associés à l'efficacité thérapeutique de l'irinotécan | |
| WO2016146254A8 (fr) | Agents destinés à être utilisés dans le traitement thérapeutique ou prophylactique de la myopie ou de l'hypermétropie | |
| MX2021009281A (es) | Metodos de deteccion de legionella. | |
| EP3935190A4 (fr) | Réactifs, procédés et kits pour identifier des femmes enceintes à risque de trouble(s) du lit placentaire | |
| FR3055339B1 (fr) | Methode de detection et d'identification in vitro d'un ou plusieurs pathogenes cibles presents dans un echantillon biologique | |
| EA201992112A1 (ru) | Способы лечения опухоли | |
| EP3400313A4 (fr) | Sous-typage multi-phénotypique d'échantillons biologiques par extinction de fluorescence et re-coloration fluorescente séquentielle | |
| MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
| ATE530668T1 (de) | Verfahren und kits zur brustkrebsprognose | |
| Kissell et al. | Enhancing Ministry & Improving Clergy Well-Being: Exploring the impact of Bowen’s Systems Coaching on the Work-Related Psychological Health of Clergy | |
| ES2640524A1 (es) | Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas | |
| JOP20210052A1 (ar) | علاج سرطان الأوعية الصفراوية | |
| Wang et al. | MYD88 L265P Mutation Detection: Analysis of Flow Cytometry Sorted Plasma and Lymphoid Cell Clones Improves Sensitivity and Specificity for WM/LPL Diagnosis | |
| Chakraborty et al. | A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents | |
| DE602004026688D1 (de) | Humane cyclooxygenase-3 und ihre verwendung | |
| NZ761242A (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf | |
| LT2017526A (lt) | Berlyno mėlynojo pasluoksnio ant titano pagrindo formavimo metodai ir jų taikymas gliukozės biologiniuose jutikliuose |